Integra LifeSciences Holdings Corporation reported $1.65B of revenue over the trailing twelve months, +1.6% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.65B (to Q2 2026). Net income: −$7.2M, trailing twelve months to Q2 2026. Free cash flow: $26M, trailing twelve months to Q2 2026. Operating margin: 3.9%, trailing twelve months to Q2 2026.

IARTIntegra LifeSciences Holdings Corporation

Healthcare

$13.44-4.9% 1Y

$13.44

$8.9052 weeks$19.87

IART as reported

Integra LifeSciences Holdings Corporation reported $1.65B of revenue over the trailing twelve months, +1.6% on the year before. 11 reported series are charted on this page, each one as filed.

$1.65B

Revenue, trailing twelve months · to Q2 2026 · +1.6% against the twelve months before

Net income: −$7.2M
Net income · −99% year on year · trailing twelve months to Q2 2026
Free cash flow: $26M
Free cash flow · −169% year on year · trailing twelve months to Q2 2026
Operating margin: 3.9%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IART, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.65B	+1.6%	Q2 2026
Net income	−$7.2M	−99%	Q2 2026
EPS	−$0.09	−99%	Q2 2026
Gross margin	53%	n/a	Q2 2026
Operating margin	3.9%	n/a	Q2 2026
Net margin	−0.46%	n/a	Q2 2026
ROE	−36%	n/a	Q2 2026
ROA	−10%	n/a	Q2 2026
ROIC	−18%	n/a	Q2 2026
Free cash flow	$26M	−169%	Q2 2026
P/E	63.9	n/a	Q2 2024 · 8 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.